Financial comparisons Legend Biotech Corporation
Equities
LEGN
US52490G1022
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.97 USD | +6.87% |
|
-0.16% | -12.74% |
| 02-23 | Gilead to buy cancer therapy developer Arcellx for up to $7.8 billion | RE |
| 02-12 | Legend Biotech Shares Lower After Rothschild & Co Redburn Downgrade | MT |
Main competitors
| Revenues (Y-1) | Net Margin (Y-1) | EBIT Margin (Y-1) | ROE (Y-1) | ROA (Y-1) | Leverage (Y-1) | ||
|---|---|---|---|---|---|---|---|
 | 627M | -28.22% | -21.76% | -15.45% | -10.06% | 13.02x | |
| 2.22B | 36.99% | -0.96% | 2.26% | 2.02% | 818.71x | |
| 5.38B | 24.08% | 29.51% | 16.78% | 12.27% | -0.97x | |
| 606M | -210.54% | -205.59% | -249.28% | - | 0.72x | |
| 2.85B | -24.18% | -47.77% | -3.3% | -2.88% | 9.36x | |
| 2.56B | 17.97% | 25.37% | 11.65% | 8.43% | -0.66x | |
| 3.69B | 25.89% | 28.63% | 20.56% | 12.29% | -1.54x | |
| 291M | -24.22% | -26.28% | -8.94% | -4.69% | -2.82x | |
| 265M | -13.8% | -7.18% | -9.46% | -9.11% | 18.95x | |
| 2.32B | 33.73% | 37.59% | 35.53% | 27.02% | -1.18x | |
| 958M | -30.08% | -31.31% | -42.49% | - | 2.15x | |
| 113M | -310.18% | -226% | - | - | - | |
| 829M | -0.2% | 11.86% | -0.5% | - | -6.61x | |
| 498M | 32.27% | 31.52% | 16.33% | 13.74% | -4x | |
| 235M | -85.53% | -78.53% | -54.06% | -26.62% | -1.54x | |
| Average | 1.56B | -37.07% | -32.06% | -20.03% | 2.04% | 60.26x | |
| Weighted average by Cap. | 2.23B | -28.16% | -30.95% | -27.64% | 4.39% | 146.73x |
- Stock Market
- Equities
- LEGN Stock
- Sector Legend Biotech Corporation
- Financial comparisons
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition